Recon: Pfizer to pay $93M to resolve Lipitor antirust complaint; FTC to examine group purchasing organizations

• The health care system is ignoring world’s most promising approach to preventing cardiovascular disease (STAT)
• Biogen, grappling with declining sales, slapped with DOJ subpoena over foreign operations (Fierce Pharma)
• FTC to probe the role of middlemen in worsening drug shortage crisis (STAT)
• Will slow uptake of Leqembi pose a risk to Biogen’s recovery? (Endpoints)
• Exclusive: Wegovy fuels sharp rise in use of weight-loss drugs for US youth (Reuters)
• Telemedicine abortion is as safe, effective as in-person care, US study finds (Reuters)
• Pfizer agrees to pay $93 mln to settle Lipitor antitrust lawsuit (Reuters)
• US FDA’s Needs To Fortify Supply Chain Among Legislative Priorities In 2025 Budget (MedTech Insight)
• HHS Releases ‘Essential’ And ‘Enhanced’ Cybersecurity Performance Goals (MedTech Insight)

• Leaked version of EFTA-India free trade deal sparks alarm over access to medicines (STAT)
• GSK wins appeal to only pay AstraZeneca royalties on some sales of cancer drug Zejula (Endpoints)
• Alvotech settles with J&J to launch Stelara biosimilar in Europe, Canada (Reuters)
• Prostate Screening: UK Industry Body Explores Role In Study, Points To Growing Diagnostics Remit (MedTech Insight)
• UK Approved Body Capacity Rises But Not For IVDs (MedTech Insight)
• EU Artificial Intelligence Final Text Confirmed By Parliament Committees (MedTech Insight)

• Stem cell study offers clue to South Asians’ increased risk of cardiovascular disease (STAT)
• GSK completes acquisition of Aiolos Bio for up to $1.4 bln (Reuters)
• Gaming Amylyx stock reactions to the next ALS drug test, and a chat with CRISPR’s CEO about a new investor (STAT)
• Biotech launches with $135 million for Vertex-competing pain medicine (STAT)
• Alnylam delays highly-anticipated ATTR readout as it changes study design (Endpoints)
• 'Obesity plus': What’s next for GLP-1s? (Endpoints)
• Apnimed, a late-stage sleep apnea biotech, eyes IPO in the second half (Endpoints)
• KalVista wants to raise $160M; Prime Medicine's upsized offering; Applied Tx's PhIII data (Endpoints)
• Aurinia fails to find buyer, will shed pipeline to focus on Lupkynis (Endpoints)
• Carolyn Bertozzi and Versant's new biotech breaks cover with $94M to use protein degraders in ADCs (Endpoints)
• Pfizer could end Lipitor antitrust saga involving Ranbaxy with $93M settlement (Endpoints)
• Aurinia to stop drug trials, cut jobs after failing to find buyer; shares tank (Reuters)

• Digital tools helped lower blood pressure in marginalized patient groups (STAT)
• Freenome raises $254M for early cancer detection tests (Endpoints)
• Canary CEO Bill Hunter talks smart knee implant progress, new heart device (MedTech Dive)
• Smiths Medical recalls syringe pumps for software malfunction (MedTech Dive)
• Masimo wins first FDA clearance for OTC medical fingertip pulse oximeter (MedTech Dive)
• FDA Clears AI Software Designed To Detect Early Signs Of Fatty Liver Disease (MedTech Insight)

• The Jewish American and Palestinian American scientists who’ve been partnering for 14 years on science’s toughest challenges (STAT)
• Long Covid research funding at NIH gets a nearly 50% boost (STAT)